1 / 1

Comparative Study of AG1024 and JNJ-38877605 on Cell Viability and Signaling Pathways

This supplementary figure presents cell viability results (%) at varying doses (µM) of AG1024 and JNJ-38877605, along with the effects on AKT and MAPK signaling pathways. The study also explores interactions with ERL, VAN, SOR, and GEF inhibitors.

zarola
Télécharger la présentation

Comparative Study of AG1024 and JNJ-38877605 on Cell Viability and Signaling Pathways

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplementary figure 5 AG1024 JNJ-38877605 A C Cell viability (%) Dose (µM) Dose (µM) AG1024 (10µm) JNJ-38877605(10µm) B D ERL-R VAN-R SOR-R ERL-R VAN-R SOR-R GEF-R GEF-R SOR-R SOR-R VAN-R ERL-R ERL-R VAN-R GEF-R GEF-R phospho AKT Phospho AKT AKT AKT phospho MAPK44/42 phospho MAPK44/42 MAPK44/42 MAPK44/42 β-actin β-actin

More Related